SCHEMBL582826

SCHEMBL582826

O=C(NCc1cc(C(F)(F)F)ccc1F)[C@](O)(c1ccccc1)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CETP P11597 1/20 0.44
MAPT P10636 3/20 0.44
HTT P42858 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.43
USP30 Q70CQ3 1/20 0.43
SUCNR1 Q9BXA5 1/20 0.43
TP53 P04637 1/20 0.42
RIPK1 Q13546 1/20 0.41
DDR1 Q08345 1/20 0.40
MAPK14 Q16539 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
IDO1 P14902 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5517353 1.00 KMT2A (0.46) KMT2ALMNAL3MBTL1NPSR1CETP
SCHEMBL5513992 1.00 KMT2A (0.46) KMT2ALMNAL3MBTL1NPSR1CETP
SCHEMBL5521185 0.93 KMT2A (0.44) KMT2ALMNAL3MBTL1NPSR1CETP
SCHEMBL582690 0.93 KMT2A (0.44) KMT2ALMNAL3MBTL1NPSR1CETP
SCHEMBL582894 0.93 KMT2A (0.44) KMT2ALMNAL3MBTL1NPSR1CETP
SCHEMBL582743 0.92 CETP (0.44) KMT2ALMNAL3MBTL1NPSR1CETP
SCHEMBL582744 0.92 CETP (0.44) KMT2ALMNAL3MBTL1NPSR1CETP
SCHEMBL582742 0.91 POLB (0.44) KMT2ALMNAL3MBTL1NPSR1CETP
SCHEMBL582729 0.88 P2RX7 (0.43) KMT2ALMNACETPMEN1SUCNR1
SCHEMBL5517336 0.88 P2RX7 (0.43) KMT2ALMNACETPMEN1SUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070133-A Pharmaceutical compositions containing androgen receptor inhibitors/antagonists, methods and uses 苏州开拓药业股份有限公司 2026-05-19 CN claimed
WO-2025051237-A1 PHARMACEUTICAL COMPOSITION CONTAINING ANDROGEN RECEPTOR INHIBITOR/ANTAGONIST, METHOD AND USE 苏州开拓药业股份有限公司 2025-03-13 WO claimed
EP-1755572-B1 N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2012-02-15 EP claimed
US-7763659-B2 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators MERCK SHARP & DOHME CORP. (US) 2010-07-27 US claimed
US-7629367-B2 Tissue-selective androgen receptor modulators (SARMs); male hypogonadism, prostate cancer, benign prostate hyperplasia, sarcopenia, rheumatoid arthritis and osteoarthritis; N-((5-cyclopropyl-2-fluoropyridin-3-yl)methyl)-2-phenylbutanamide for example MERCK & CO., INC. (US) 2009-12-08 US claimed
JP-2008501800-A 2008-01-24 JP claimed
US-7268153-B2 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators MERCK & CO., INC. (US) 2007-09-11 US claimed
EP-1755572-A2 N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2007-02-28 EP claimed
WO-2005120477-A2 N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2005-12-22 WO claimed
CN-122070133-A Pharmaceutical compositions containing androgen receptor inhibitors/antagonists, methods and uses 苏州开拓药业股份有限公司 2026-05-19 CN disclosed
WO-2025051237-A1 PHARMACEUTICAL COMPOSITION CONTAINING ANDROGEN RECEPTOR INHIBITOR/ANTAGONIST, METHOD AND USE 苏州开拓药业股份有限公司 2025-03-13 WO disclosed
EP-1755572-B1 N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2012-02-15 EP disclosed
EP-1755572-B1 N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2012-02-15 EP disclosed
US-7763659-B2 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators MERCK SHARP & DOHME CORP. (US) 2010-07-27 US disclosed
US-20070225229-A1 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators MERCK SHARP & DOHME CORP. 2007-09-27 US disclosed
US-7268153-B2 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators MERCK & CO., INC. (US) 2007-09-11 US disclosed
US-7268153-B2 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators MERCK & CO., INC. (US) 2007-09-11 US disclosed
EP-1755572-A2 N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2007-02-28 EP disclosed
WO-2005120477-A2 N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2005-12-22 WO disclosed
US-20050277681-A1 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators MERCK SHARP & DOHME CORP. 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277681-A1 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators SHBG, AR, BRCA1 KMT2A 1189/4885LMNA 1363/4885L3MBTL1 1815/4885
US-20070225229-A1 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators SHBG, AR, BRCA1 KMT2A 1189/4885LMNA 1363/4885L3MBTL1 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.